大剂量阿糖胞苷治疗急性髓性白血病缓解后患者15例分析  

Effects of High-dose Cytarabine Treating 15 Cases Involving Remission of Acute Myeloid Leukemia

作　　者：祝辉[1] 高峰[2] 

机构地区：[1]辽宁省沈阳市第四人民医院血液科,110031 [2]中国医科大学附属第一医院

出　　处：《中国全科医学》2006年第24期2070-2071,共2页Chinese General Practice

摘　　要：目的 观察急性髓性白血病（AML）缓解后应用大剂量阿糖胞苷（HD—Ara—C）联合常规化疗治疗的疗效。方法 将29例AML患者随机分为治疗组和对照组。治疗组15例患者在常规化疗基础上第1、3、5d用HD—Ara—C持续3h以上静脉滴注，1—2次／年。对照组患者行常规化疗。比较两组患者治疗后1年、3年和5年的无病生存（DFS）情况。结果 两组患者治疗后1年、3年和5年的DFS情况间差别均有显著性意义（P〈0．01）。结论 HD—Ara—C用于AML缓解后的维持强化治疗疗效较好，可延长患者的DFS期。Objective To observe the therapeutic effects of high - dose cytarabine （ HD - Ara - C） in the treatment of patients with remission of acute myeloid leukemia （AML）. Methods 29 cases with AML were randomly divided into treatment group （15 cases） and control group （14 cases）. Patients in treatment group were carried HD- Ara- C intravenously On the first, third and fifth day, at least three hours, once or twice per year on the basis of routine chemical therapy while patients in control group were only carried routine chemical therapy. The disease - free survival （DFS） after the first, third and fifth year between two groups were compared. Results The difference of DFS after the first, third and fifth year between two groups was significant （ P 〈 0.01 ）. Conclusion HD - Ara - C has better therapeutic effect for patients with forced treatment after the remission of AML, which can prolong the time of DFS.

关 键 词：大剂量阿糖胞苷 白血病 髓样 急性 无病生存 

分 类 号：R733.712[医药卫生—肿瘤]